AMRN


Why Did Amarin (AMRN) Stock Sink After Earnings? Analysts Explain

Last week, anti-cholesterol drugmaker Amarin (AMRN) reported a better-than-expected $0.07-per-share loss on $73.

Why Did Amarin (AMRN) Stock Sink After Earnings? Analysts Explain

Anti-cholesterol drugmaker Amarin (AMRN) reported a better-than-expected $0.07-per-share loss on Wednesday on $73.

Analyst Sings the Praises of Amarin (AMRN) Stock Following ADA Endorsement

With primary care clinicians playing an ever-increasing role in the management of diabetes, staying on top of new developments in the American Diabetes …

Stifel on Amarin (AMRN): Nothing Fishy About This Stock — It’s a Buy!

Do you have high cholesterol? Investors in Amarin (AMRN) kind of hope that you do — but ideally, not too high.

Amarin (AMRN): New Survey Offers Insight Into Vascepa Market Opportunity

Amarin’s (AMRN) Vascepa is currently approved to treat around 3.8 million Americans with high triglycerides, as an adjunct to diet.

Should You Buy Amarin (AMRN) Stock? 4 Pros, 4 Cons

Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …

Amarin (AMRN): Management Is Flying in the Dark

A lot of Amarin (AMRN) stock bulls expected shares to fly up toward $30 following shockingly good results of the company’s Reduce-It cardiovascular …

Amarin (AMRN) Stock: This Bull Isn’t Bullish Enough

Amarin (AMRN) has been Wall Street’s biggest standout of 2018, with shares skyrocketing nearly 240%. The biggest question for investors, then, is whether …

Here’s Why Amarin (AMRN) Stock Soared Today

Shares of Amarin (AMRN), an Irish biopharma that markets a prescription fish oil medication called Vascepa, are on the move following the company’s …

Why Amarin (AMRN) Stock May Be a Good Buy Right Now

Amarin (AMRN) has had a lot of attention over its fish oil pill Vascepa, which aims to help those with cardiovascular problems and …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts